Home > Insider Trading > Filing (0001144204-19-031542)

Filing Details

Accession Number:: 0001144204-19-031542
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-06-19 18:24:24
Reporting Period:: 2019-06-17

Accepted Time:: 2019-06-19 18:24:24
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1740547	Urovant Sciences Ltd.	UROV	()	L3

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1636684	Ltd. Holdings Dexxon	1 Dexcel Street Or Akiva L3 3060000	No	No	Yes	No
1636701	Dan Oren	1 Dexcel Street Or Akiva L3 3060000	No	No	Yes	No
1720007	Ltd. Technologies Pharma Dexcel	1 Dexcel Street Or Akiva L3 3060000	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares, $0.000037453 Par Value Per Share	Acquisiton	2019-06-17	6,541	$8.53	22,848,350	No	4	P	Indirect	See footnotes
Common Shares	Acquisiton	2019-06-18	6,706	$8.21	22,855,056	No	4	P	Indirect	See footnotes
Common Shares	Acquisiton	2019-06-19	4,957	$8.17	22,860,013	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Footnotes

Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares.
Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise.
Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons.
The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $8.11 to $8.70, inclusive.
The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $8.09 to $8.29, inclusive.
The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $8.00 to $8.27, inclusive.